Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
Immuron Limited - American Depositary Shares (IMRN)
US:NASDAQ Investor Relations:
immuron.com/investor-centre/business-overview
Company Research
Source: GlobeNewswire
Key Highlights: First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of IMM-529 for the treatment of CDI CDI is one of the top superbugs challenging the healthcare industry as its germs spread easily, often requires antibiotic treatment, and leaves patients vulnerable to infections 450,000 CDI cases reported annually in the USA increasing healthcare costs from $3K to $10K per patient MELBOURNE, Australia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immune-therapeutics for the treatment of gut mediated diseases, today announced the enrollment of the first patients into the first-in-human IMM-529 clinical study for the treatment of Clostridium Difficile Infection (CDI). Most commonly affecting older adults after use of antibiotic m
Show less
Read more
Impact Snapshot
Event Time:
IMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRN alerts
High impacting Immuron Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMRN
News
- We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Immuron Presentation Australian Biologics Festival 2024GlobeNewswire
- Immuron achieves record Travelan® sales [Yahoo! Finance]Yahoo! Finance
- Immuron achieves record Travelan® salesGlobeNewswire
- Immuron CEO, Steven Lydeamore Investor Webinar Presentation [Yahoo! Finance]Yahoo! Finance
IMRN
Sec Filings
- 3/14/24 - Form 6-K
- 3/5/24 - Form 6-K
- 2/28/24 - Form 6-K
- IMRN's page on the SEC website